A Study of [14C]-LY3023703 in Healthy Participants
Disposition of [14C]-LY3023703 Following Oral Administration in Healthy Subjects
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53704
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Participants will either be sterile or, if sexually active, agree to use approved methods of contraception from the day before dosing until 3 months after the follow-up assessment
- Participants will refrain from sperm donation from the day before dosing until 3 months after the follow-up assessment
- Have a body mass index (BMI) of 18.5 to 32.0 kilogram per meter square (kg/m^2)
- Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator
- Have given written informed consent approved by Lilly and the IRB governing the site
Exclusion Criteria:
- Are currently enrolled in, have participated, within the last 30 days, in a clinical trial involving an investigational product, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
- Are participants who have previously completed or withdrawn from this study or any other study investigating LY3023703, and have previously received the investigational product
- Have known allergies to LY3023703, related compounds or any components of the formulation, or history of significant atopy
- Have recent or ongoing gastrointestinal (GI) symptoms or illnesses, have a history of GI bleeding or perforation, related to previous nonsteroidal anti-inflammatory drug (NSAID) or cyclooxygenase (COX)2 inhibitor therapy or have active or history of recurrent peptic ulcer/hemorrhage (2 or more distinct episodes of proven ulceration or bleeding)
- Have a history of intolerance to NSAIDs or aspirin
- Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
- Show evidence of alanine aminotransferase or aspartate aminotransferase levels above the normal ranges, confirmed on repeat, or a history of elevated and abnormal liver tests
- Have intended use of over-the-counter medications or prescription medication within 14 days prior to dosing. Also within 30 days prior to dosing, any drugs and dietary items that are known inducers or inhibitors of cytochrome P450 (CYP) 3A or CYP2J2 or other drugs that may affect the disposition of LY3023703 or increase risk for complications from the study
- Have consumed herbal supplements within 14 days prior to admission or grapefruit juice, grapefruits, grapefruit-containing products, Seville orange juice, Seville oranges, star fruit, or star fruit juice within 7 days prior to dosing or intend to consume during the study
- Have donated blood of more than 500 milliliter (mL) within the last month
- Have participated in a [14C]-study within the last 6 months prior to admission for this study
- Exposure to significant radiation within 12 months prior to dose (for example, serial X-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring)
- A positive alcohol breathalyzer test
- A positive cotinine test
- Are unwilling to refrain from consuming xanthine-containing food and drink from 48 hours prior to admission until discharge from the Clinical Research Unit (CRU)
- Have a defecation pattern less than once per 2 days or acute constipation within 3 weeks of the day before dosing
- In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Ciencia básica
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: [^14C]-LY3023703
Single oral dose of 15 mg LY3023703, containing approximately 100 µCi [^14C] labeled drug, administered as an oral solution.
|
Administered orally
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Fecal Excretion of LY3023703 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Periodo de tiempo: Predose up to 168 hours post dose
|
Predose up to 168 hours post dose
|
|
Urinary Excretion of LY3023703 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Periodo de tiempo: Predose up to 168 hours post dose
|
Predose up to 168 hours post dose
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Pharmacokinetics of LY3023703 and Radioactivity Maximum Observed Concentration (Cmax)
Periodo de tiempo: Predose up to 168 hours post dose
|
Predose up to 168 hours post dose
|
|
Pharmacokinetics of LY3023703 and Radioactivity Time of Maximum Observed Concentration (Tmax)
Periodo de tiempo: Predose up to 168 hours post dose
|
Predose up to 168 hours post dose
|
|
Pharmacokinetics of LY3023703 and Radioactivity Area Under The Concentration-Time Curve From Time Zero to the Last Timepoint With a Measurable Concentration [AUC (0 to Tlast)]
Periodo de tiempo: Predose up to 168 hours post dose
|
Predose up to 168 hours post dose
|
|
Relative Abundance of LY3023703 and the Metabolites of LY3023703 in Urine and Feces
Periodo de tiempo: Predose up to 168 hours post dose
|
Predose up to 168 hours post dose
|
|
Relative Abundance of LY3023703 and the Metabolites of LY3023703 in Plasma
Periodo de tiempo: One hour post-dose up to 72 hours post dose
|
One hour post-dose up to 72 hours post dose
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
Otros números de identificación del estudio
- 15097
- I6H-MC-MCBD (Otro identificador: Eli Lilly and Company)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .